Risk assessment on the spread of carbapenemase-producing Enterobacteriaceae (CPE) through patient transfer between healthcare facilities, with special emphasis on cross-border transfer
The purpose of this risk assessment is to evaluate the risk to the citizens of Europe of CPE spread through patient mobility and to assess the effectiveness of infection control methods to stop the spread of CPE within healthcare institutions.
Systematic review of the effectiveness of infection control measures to prevent the transmission of extended-spectrum beta-lactamase-producing Enterobacteriaceae through cross-border transfer of patients
This systematic review seeks to identify evidence for the effectiveness of targeted infection control measures to control the spread and transmission of ESBL-E when transferring patients between healthcare settings, especially when the transfer is cross-border.
Invasive cardiovascular infection by Mycobacterium chimaera potentially associated with heater-cooler units used during cardiac surgery, 30 April 2015
Since 2011, cases of infection caused by Mycobacterium chimaera have been detected in patients having previously undergone cardiac surgery in Europe.
Rapid risk assessment: Carbapenem-resistant Enterobacteriaceae, 14 April 2016
This rapid risk assessment provides several options to reduce the risk of CRE, e.g. treatment options, transmission prevention and measures related to the healthcare system.
ECDC/EMEA Joint Technical Report: The bacterial challenge: time to react
Rapid Risk Assessment: Plasmid-mediated colistin resistance in Enterobacteriaceae, 15 June 2016
This document assesses the risk for patients and healthcare systems in the EU/EEA due to the global mcr-1 plasmid-mediated gene epidemic.
Last-line antibiotics are failing: options to address this urgent threat to patients and healthcare systems
This briefing aims to draw the attention of policymakers to examples of measures that can be taken at national and local levels to halt the spread of highly resistant bacteria, especially those resistant to ‘last-line’ antibiotics.
Rapid risk assessment: Carbapenem-resistant Acinetobacter baumannii in healthcare settings – 8 December 2016
This risk assessment provides an overview of the epidemiological situation in Europe and describes a number of response options.
Proposals for EU guidelines on the prudent use of antimicrobials in humans
Proposal for EU guidelines on the prudent use of antimicrobials in human medicine, including generic principles of good practice on the appropriate use of antimicrobial agents in human medical practice in the EU.
Rapid risk assessment: Candida auris in healthcare settings – Europe
This rapid risk assessment update appraises the risk for spread of C. auris in hospitals in the European Union and European Economic Area (EU/EEA) countries